Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Fair Value, by Balance Sheet Grouping

The following tables present the Company’s hierarchy for its assets measured at fair value as of December 31, 2021 and 2020:

	December 31, 2021
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	57,357	$	57,357	$	—	$	—
Convertible promissory note	4,021		—		—		4,021
Embedded derivative asset in convertible promissory note	962		—		—		962
Investment in Tyme	6,030		6,030		—		—
Total financial assets	$	68,370	$	63,387	$	—	$	4,983

	December 31, 2020
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	79,682	$	79,682	$	—	$	—
Investment in Tyme	12,200		12,200
Total financial assets	$	91,882	$	91,882	$	—	$	—

Schedule of Revenue by Major Customers by Reporting Segments

The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:

	Year Ended December 31,
	2021		2020		2019
Net revenues
Cephalon, Inc. (Teva) - See Revenue Recognition	66	%	67	%	77	%
Other	34	%	33	%	23	%
	100	%	100	%	100	%

	December 31,
	2021		2020
Accounts receivable
Cephalon, Inc. (Teva) - See Revenue Recognition	63	%	58	%
Other	37	%	42	%
	100	%	100	%

Revenue from External Customers by Products and Services

The Company recorded product sales, net as follows:

	Year Ended December 31,
	2021		2020		2019
	(in thousands)
Bendeka	$	11,167	$	15,439	$	31,182
Belrapzo	23,728		27,527		29,665
Ryanodex	25,271		28,268		13,039
Other	4,857		1,089		103
Product sales, net	$	65,023	$	72,323	$	73,989

Summary of Sales Allowances and Related Accruals

The following table provides a summary roll-forward of the Company's net product revenue allowances and related reserves for the years ended December 31, 2021 and 2020, on the consolidated balance sheets (in thousands):

	Chargebacks		Commercial Rebates		Medicaid Rebates		Product Returns		Wholesaler Fees and Other Incentives		Total
Balance at December 31, 2019	$	2,988	$	1,131	$	567	$	2,403	$	2,011	$	9,100
Provisions / Adjustments	20,368		1,243		484		(391)		8,526		30,230
Charges processed / Payments	(21,067)		(602)		(367)		(346)		(5,146)		(27,528)
Balance at December 31, 2020	$	2,289	$	1,772	$	684	$	1,666	$	5,391	$	11,802
Provisions / Adjustments	27,402		3,042		268		2,531		9,650		42,893
Charges processed / Payments	(25,852)		(2,838)		(332)		(2,674)		(13,070)		(44,766)
Balance at December 31, 2021	$	3,839	$	1,976	$	620	$	1,523	$	1,971	$	9,929

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The anti-dilutive common shares equivalents outstanding at December 31, 2021, 2020, and 2019 were as follows:

	Year Ended December 31,
	2021	2020	2019
Options	2,336,586	2,767,501	2,454,077
Restricted stock units	98,416	207,177	—
Total	2,435,002	2,974,678	2,454,077

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation for basic and diluted net (loss) income per share for December 31, 2021, 2020, and 2019:

	Year Ended December 31,
	2021		2020		2019
Numerator
Numerator for basic and diluted earnings per share-net (loss) income	$	(8,627)	11,989		$	14,313
Denominator
Basic weighted average common shares outstanding	13,051,095		13,481,525		13,754,516
Dilutive effect of stock options	—		289,868		384,217
Diluted weighted average common shares outstanding	13,051,095		13,771,393		14,138,733
Basic net (loss) income per share
Basic net (loss) income per share	$	(0.66)	$	0.89	$	1.04
Diluted net (loss) income per share
Diluted net (loss) income per share	$	(0.66)	$	0.87	$	1.01